Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder

Serkan Kapancık; Elif Abanoz; Ahmet Ozan Kaleci

doi:10.47582/jompac.1864383

Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder

Abstract

Aims: Anxiety disorders are quite common in children and adolescents. Affecting approximately 6.5% of children and adolescents, this disorder stems from a complex interplay of genetic predisposition and environmental risk factors. Since adenosine has a role in suppressing anxiety, increased adenosine degradation, followed by increased degradation of hypoxanthine and xanthine, and subsequently increased reactive oxygen species, which are associated with anxiety, may contribute to the biology of anxiety in children. Therefore, in our study, we aimed to investigate the activity levels of the adenosine degrading enzyme adenosine deaminase (ADA) and the hypoxanthine and xanthine degrading enzyme xanthine oxidase (XO) to determine whether changes in the activity of these two enzymes play a role in anxiety in children. Methods: The study design was a cross-sectional case-control study. ADA and XO enzyme activity levels were spectrophotometrically analyzed in serum samples obtained from children with anxiety and children in the control group. Results: ADA activity was measured as 22.12±2.51 U/L in children with anxiety, while this value was determined as 14.90±1.98 U/L in the control group (p<0.001). XO activity was found to be 5.38±0.86 U/L in children with anxiety and 4.24±0.62 U/L in the control group (p<0.001). Conclusion: Because increased ADA activity levels lead to an imbalance in the purinergic signaling system, and increased XO activity leads to an increase in reactive oxygen species. may contribute to the development of anxiety in children.

Keywords

Ethical Statement

Before starting the research study, an ethical permission document dated 12.06.2025 and numbered 2025-06/97 was obtained from Sivas Cumhuriyet University Health Sciences Research Ethics Committe.

References

Javaid SF, Hashim IJ, Hashim MJ, Stip E, Samad MA., Ahbabi AA. Epidemiology of anxiety disorders: global burden and sociodemographic associations. Middle East Curr Psychiatry. 2023;30(1):30-44. doi:10.1186/s43045-023-00315-3
Michael T, Zetsche U, Margraf J. Epidemiology of anxiety disorders. Psychiatry. 2007;6(4):136-142. doi:10.1016/j.mppsy.2007.01.007
Rapee RM, Creswell C, Kendall PC, Pine DS, Waters AM. Anxiety disorders in children and adolescents: a summary and overview of the literature. Behav Res Ther. 2023;168:104376. doi:10.1016/j.brat.2023.104376
Lewinsohn PM, Gotlib IH, Lewinsohn M, Seeley JR, Allen NB. Gender differences in anxiety disorders and anxiety symptoms in adolescents. J Abnorm Psychol. 1998;107(1):109-117. doi:10.1037/0021-843X.107.1.109
Meier SM, Deckert J. Genetics of anxiety disorders. Curr Psychiatry Rep. 2019;21(3):16. doi:10.1007/s11920-019-1002-7
Cheffer A, Castillo ARG, Corrêa-Velloso J, et al. Purinergic system in psychiatric diseases. Mol Psychiatry. 2018;23(1):94-106. doi:10.1038/mp. 2017.188
Boison D. Adenosine as a neuromodulator in neurological diseases. Curr Opin Pharmacol. 2008;8(1):2-7. doi:10.1016/j.coph.2007.09.002
Sperlagh B, Csolle C, Ando RD, Goloncser F, Kittel A, Baranyi M. The role of purinergic signaling in depressive disorders. Neuropsychopharmacol Hung. 2012;14(4):231-238.

Cristalli G, Costanzi S, Lambertucci C, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev. 2001;21(2):105-128. doi:10.1002/1098-1128
Kostić DA, Dimitrijević DS, Stojanović GS, Palić IR, Đorđević AS, Ickovski JD. Xanthine oxidase: isolation, assays of activity, and inhibition. J Chem. 2015;2015(1):294858. doi:10.1155/2015/294858
Pasquini S, Contri C, Merighi S, et al. Adenosine receptors in neuropsychiatric disorders: fine regulators of neurotransmission and potential therapeutic targets. Int J Mol Sci. 2022;23(3):1219. doi:10.3390/ijms23031219
Yamada K, Kobayashi M, Kanda T. Involvement of adenosine A2A receptors in depression and anxiety. Int Rev Neurobiol. 2014;119:373-393. doi:10.1016/B978-0-12-801022-8.00015-5
Prediger RD, da Silva GE, Batista LC, Bittencourt AL, Takahashi RN. Activation of adenosine A1 receptors reduces anxiety-like behavior during acute ethanol withdrawal (hangover) in mice. Neuropsychopharmacology. 2006;31(10):2210-2220. doi:10.1038/sj.npp. 1301001
Fedoce ADG, Ferreira F, Bota RG, Bonet-Costa V, Sun PY, Davies KJ. The role of oxidative stress in anxiety disorder: cause or consequence? Free Radic Res. 2018;52(7):737-750. doi:10.1080/10715762.2018.1475733
Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: relationship and cellular pathways. Oxid Med Cell Longev. 2009;2(2):63-67. doi:10.4161/oxim.2.2.7944
Giusti G, Galanti B. Colorimetric method. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. Vol 3. Weinheim: Verlag Chemie; 1984: 315-323.
Massey V, Brumby PE, Komai H, Palmer G. Studies on milk xanthine oxidase: some spectral and kinetic properties. J Biol Chem. 1969;244(7): 1682-1691. doi:10.1016/S0021-9258(18)91738-2
Herken H, Akyol O, Yilmaz HR, et al. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol. 2006;21(1): 53-59. doi:10.1002/hup.742
Yarpuz AY, Yilmaz A, Soykan A, Elgün S, Kumbasar H. Levels of adenosine deaminase and dipeptidyl peptidase IV in patients with panic disorder. Turk Psikiyatri Derg. 2008;19(2):1-7.
Michel TM, Camara S, Tatschner T, et al. Increased xanthine oxidase in the thalamus and putamen in depression. World J Biol Psychia. 2010; 11(2–2):314-320. doi:10.3109/15622970802123695
Cieślak M, Czarnecka J, Roszek K. The roles of purinergic signaling in psychiatric disorders. Acta Biochimica Polonica. 2016;63(1):1-9. doi:10. 18388/abp.2015_1004
Wardas J. Neuroprotective role of adenosine in the CNS. Pol J Pharmacol. 2002;54(4):313-326.
Han C, Wu Y, Rong J, Xia Q, Du D. Unveiling the Emerging role of xanthine oxidase in acute pancreatitis: beyond reactive oxygen species. Antioxidants. 2025;14(1):95. doi:10.3390/antiox14010095
Krolow R, Arcego DM, Noschang C, Weis SN, Dalmaz C. Oxidative imbalance and anxiety disorders. Curr Neuropharmacol. 2014;12(2):193-204. doi:10.2174/1570159X11666131120223530
Guney E, Ceylan MF, Tektas A, et al. Oxidative stress in children and adolescents with anxiety disorders. J Affect Disord. 2014;156:62-66. doi: 10.1016/j.jad.2013.11.016

Details

Primary Language

English

Subjects

Child and Adolescent Psychiatry

Journal Section

Research Article

Authors

Serkan Kapancık ^*
0000-0003-3019-4275
Türkiye

Elif Abanoz
0000-0002-9214-4735
Türkiye

Ahmet Ozan Kaleci
0000-0003-4514-6209
Türkiye

Publication Date

February 20, 2026

Submission Date

January 15, 2026

Acceptance Date

February 10, 2026

Published in Issue

Year 2026 Volume: 7 Number: 1

DOI

https://doi.org/10.47582/jompac.1864383

IZ

https://izlik.org/JA65BU86DB

Cite

RIS / Bibtex

APA

Kapancık, S., Abanoz, E., & Kaleci, A. O. (2026). Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. Journal of Medicine and Palliative Care, 7(1), 148-153. https://doi.org/10.47582/jompac.1864383

AMA

1.Kapancık S, Abanoz E, Kaleci AO. Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. J Med Palliat Care / JOMPAC / jompac. 2026;7(1):148-153. doi:10.47582/jompac.1864383

Chicago

Kapancık, Serkan, Elif Abanoz, and Ahmet Ozan Kaleci. 2026. “Adenosine Deaminase and Xanthine Oxidase Activity Levels in Children With Anxiety Disorder”. Journal of Medicine and Palliative Care 7 (1): 148-53. https://doi.org/10.47582/jompac.1864383.

EndNote

Kapancık S, Abanoz E, Kaleci AO (February 1, 2026) Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. Journal of Medicine and Palliative Care 7 1 148–153.

IEEE

[1]S. Kapancık, E. Abanoz, and A. O. Kaleci, “Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder”, J Med Palliat Care / JOMPAC / jompac, vol. 7, no. 1, pp. 148–153, Feb. 2026, doi: 10.47582/jompac.1864383.

ISNAD

Kapancık, Serkan - Abanoz, Elif - Kaleci, Ahmet Ozan. “Adenosine Deaminase and Xanthine Oxidase Activity Levels in Children With Anxiety Disorder”. Journal of Medicine and Palliative Care 7/1 (February 1, 2026): 148-153. https://doi.org/10.47582/jompac.1864383.

JAMA

1.Kapancık S, Abanoz E, Kaleci AO. Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. J Med Palliat Care / JOMPAC / jompac. 2026;7:148–153.

MLA

Kapancık, Serkan, et al. “Adenosine Deaminase and Xanthine Oxidase Activity Levels in Children With Anxiety Disorder”. Journal of Medicine and Palliative Care, vol. 7, no. 1, Feb. 2026, pp. 148-53, doi:10.47582/jompac.1864383.

Vancouver

1.Serkan Kapancık, Elif Abanoz, Ahmet Ozan Kaleci. Adenosine deaminase and xanthine oxidase activity levels in children with anxiety disorder. J Med Palliat Care / JOMPAC / jompac. 2026 Feb. 1;7(1):148-53. doi:10.47582/jompac.1864383